Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnil PhilipIAIvy Abraham

Discussion

Loading...

Member takes

Overview

Systematic review demonstrates Gilteritinib maintenance therapy enhances relapse-free survival in FLT3-mutated acute myeloid leukemia patients, indicating its post-transplant potential.

Key Points

  • Gilteritinib maintenance therapy significantly improves relapse-free survival in FLT3-mutated AML.
  • Pooled risk ratios indicate an RFS improvement with RR 1.32; 95% CI: 1.07–1.62 from 552 patients.
  • The analysis included observational studies and randomized controlled trials from multiple databases.
  • Findings support Gilteritinib use after allo-HSCT, but highlight the need for larger trials regarding GVHD.

Cite This Study

Philip et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d342https://doi.org/10.1182/blood-2025-6977
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  2. 2Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  3. 3Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience2025 · 6 citations
  4. 4Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 15062025 · 1 citations
  5. 5A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study2025